CO2-reduziertes Salbutamol-Dosieraerosol: positive Ergebnisse der Phase-III-Zulassungsstudie

Allergo Journal 2026

View at publisher

Authors: Redaktion Facharztmagazine

DOI: 10.1007/s15007-026-6630-8

Cited by: 0

Fields of Study & Subjects

Asthma and respiratory diseases Inhalation and Respiratory Drug Delivery Chronic Obstructive Pulmonary Disease (COPD) Research